Sodium-glucose cotransporter 2 inhibitors versus insulin therapy in companion animals with diabetes mellitus: a systematic review of current evidence and therapeutic perspectives
Authors:
- Luminița-Diana HrițcuLHLuminița-Diana Hrițcu
- Eugenia DumitrescuEDEugenia Dumitrescu
- Florin NechiforFNFlorin Nechifor
- Vasile BoghianVBVasile Boghian
- Ioana Ștefania CucoșICIoana Ștefania Cucoș
- Teodor-Daniel HrițcuTHTeodor-Daniel Hrițcu
- Iulia StratonISIulia Straton
- Marius Stelian IlieMarius Stelian Ilie
- Alina AntonAAAlina Anton
- Alexandra Andreea CherșUnaruACAlexandra Andreea CherșUnaru
- Sorin Ioan BeșChea ChiriacSCSorin Ioan BeșChea Chiriac
- Mihaela Claudia SpataruMSMihaela Claudia Spataru
- 30 September 2026
- journal article
- review article
- Published by Universitatea de Stiintele Vietii Regele Mihai I din Timisoara in Romanian Journal of Veterinary Sciences
- Vol. 59 (3) , 541-557
Abstract
Diabetes mellitus in companion animals represents a complex endocrine disorder with increasing prevalence, particularly in dogs and cats, requiring individualized and species-specific therapeutic approaches. This systematic review was conducted in accordance with the PRISMA 2020 Statement and compares two major therapeutic strategies—insulin therapy and sodium–glucose cotransporter 2 (SGLT2) inhibitors—while also analyzing factors influencing treatment selection, safety profiles, and emerging therapeutic perspectives. Insulin remains the cornerstone of diabetes management in both dogs and cats, providing reliable glycemic control across all disease stages, although its use is limited by the risk of hypoglycemia and the need for injectable administration and continuous monitoring. In contrast, SGLT2 inhibitors offer a novel oral, insulin-independent approach that improves owner compliance and demonstrates promising efficacy in selected stable feline patients, but their use is restricted by the risk of euglycemic ketoacidosis and limited applicability in insulin-dependent diabetes. Therapeutic decision-making is influenced by multiple factors, including species differences, disease pathophysiology, comorbidities, hepatic function, clinical experience, and owner-related constraints. Emerging therapies such as stem cell therapy, gene therapy, GLP-1 analogs, and advanced insulin delivery systems highlight the evolving landscape of veterinary diabetology and the potential for more personalized and regenerative treatment strategies in the future.Keywords
This publication has 43 references indexed in Scilit:
- The Future of Diabetes TherapiesVeterinary Clinics of North America: Small Animal Practice, 2023
- Concise Review: Canine Diabetes Mellitus as a Translational Model for Innovative Regenerative Medicine ApproachesStem Cells Translational Medicine, 2019
- Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in DogsMolecular Therapy - Methods & Clinical Development, 2017
- Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated DiabetesDiabetes Therapy, 2016
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia, 2015
- Feline Diabetes Mellitus2015
- Diabetes and Weight in Comparative Studies of Bariatric Surgery vs Conventional Medical Therapy: A Systematic Review and Meta-AnalysisObesity Surgery, 2013
- Re-Orientation of Clinical Research in Traumatic Brain Injury: Report of an International Workshop on Comparative Effectiveness ResearchJournal of Neurotrauma, 2012
- 'Human' insulin versus animal insulin in people with diabetes mellitus2003
- Comparative aspects of diabetes mellitus in dogs and catsMolecular and Cellular Endocrinology, 2002